• 930 notifiable conditions reported (344 pertussis, 14 hepatitis A and five measles) in NSW;
• 1,164 consultations at cruise ships; • 12,000 consultations at Olympic venue medical facilities;
• 7,000 food safety inspection of 1,066 food outlets at Olympic venues;
• 119 environmental inspections;
• 36 cruise ship inspections; • 4,000 medical interpreter occasions of service.
Jenny Davis and Janis Shaw National Centre for Aboriginal and Torres Strait Islander Statistics Australian Bureau of Statistics, Darwin
Collectors of health data across all agencies are the targets of a national awareness campaign aimed at improving the quality, completeness and coverage of indigenous health information.
The National Centre for Aboriginal and Torres Strait Islander Statistics (NCATSIS)-based at the Australian Bureau of Statistics (ABS) office in Darwin-is a key player in supporting the Indigenous Status Awareness Campaign, and is disseminating a package of campaign material including special pamphlets and a poster.
In partnership with the Australian Institute of Health and Welfare (AIHW), the ABS has developed a range of resources to help health service providers improve the accuracy of the data they collect about peoples' indigenous status and other data variables. The campaign stresses that good data quality is best achieved by following four steps:
• adoption of a standard question on indigenous status; • provision of training and support for data collectors; • raising public awareness on the issue;
• assessing the accuracy of the data when it is collected.
A standard question was developed by the ABS to help ensure consistency in collecting data on indigenous issues. However, research has indicated that health professionals and health service data collectors can experience difficulty when asking the question:
INDIGENOUS STATUS A KEY ISSUE FOR HEALTH SERVICES
This may occur if asking the question makes data collectors feel awkward, or if they feel the question is sensitive and may upset the person being questioned. Some people collecting information from clients have also said they do not know how to answer client queries about why the question is being asked, or how to manage some client reaction to the question. In developing best practice methods in data collection it is essential to train collectors to address issues surrounding the collection of indigenous status, particularly:
• understanding the importance of asking the indigenous status question;
• knowing how to ask the question;
• feeling adequately equipped with information to manage client queries and responses.
Raising general client awareness supports staff collecting data and helps them manage client queries. Materials available to assist include two pamphlets:
• one targets all clients of health services and explains why the question is being asked;
• one targets health providers and gives information on the importance of asking the question.
RELEASE OF NSW PUBLIC HEALTH BULLETIN DISCUSSION PAPER
The NSW Public Health Bulletin was established in May 1990 and has been in continuous production ever since. Throughout this period it has supported public health action in New South Wales. This month a discussion paper was released which makes recommendations regarding the future direction of the Bulletin. The discussion paper is intended to stimulate a broad discussion and readers' comments are welcome. The comments we receive will help to shape a survey of the Bulletin's readership to be conducted in 2001. The purpose of this readership survey will be to ensure that the NSW Public Health Bulletin continues to be a useful and respected tool of the public health workforce in New South Wales. Copies of the discussion paper are available from Michael Giffin, and can be obtained by phoning (02) 9391 9241; by faxing (02) 9391 9232, or by emailing mgiff@doh.health.nsw.gov.au. The discussion paper is also available from the NSW Department of Health's Web site at www.health.nsw.gov.au/public-health/phb/phb.html. Reader's comments on the discussion paper should be received by 2nd March 2001. To assist in other ways the ABS provides related services through its State regional offices, including:
Are you of Aboriginal or Torres Strait islander origin?

BACKGROUND
The poor health status of Aboriginal and Torres Strait Islander peoples is well documented. Aboriginal infants have lower birth-weights, and higher rates of stillbirth, neonatal and postnatal death compared with nonAboriginal infants. Aboriginal mothers represent nearly 30 per cent of all maternal deaths but comprise less than three per cent of all deliveries. Chronic diseases are more common among Aboriginals and Torres Strait Islanders, particularly diabetes, renal failure, and eye and ear problems. Aboriginal and Torres Strait Islander peoples are at significantly increased risk of death due to circulatory diseases, respiratory illnesses, injuries and poisoning, and cancer when compared with other Australians. The average estimated life expectancy of Aboriginals and Torres Strait Islanders continues to be around [15] [16] [17] [18] [19] [20] years below that of non-indigenous
IMPROVING THE IDENTIFICATION OF ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLES IN HEALTH-RELATED INFORMATION COLLECTION SYSTEMS IN NSW
Australians, with estimates of 57 years for indigenous males and 62 years for indigenous females. 1, 2, 3 Accurate and reliable information is critical to our efforts to improve the health outcomes of Aboriginal and Torres Strait Islander peoples. However, the quality of much of the available information is poor. One of the most important reasons for this is the under-identification of Aboriginal and Torres Strait Islander peoples in most health-related information collection systems. For example, it has been estimated that the NSW Hospital Inpatient Statistics Collection (ISC) under-enumerates Aboriginals and Torres Strait Islanders by 33 per cent. 4 This problem is further compounded by inconsistent collection practices when the data are collected, in particular the use of various questions about Aboriginal origin, descent and identification.
The inaccuracy and unreliability of these data seriously affect their use for planning, evaluation and monitoring purposes at local, State and national levels. In this regard it is of particular concern that 'national' reports about Aboriginal and Torres Strait Islander health often do not include NSW health statistics due to problems with data quality. As a result, the 25 per cent of Aboriginal Australians who reside in NSW are not being represented in the national picture.
BETTER PRACTICE GUIDELINES
The NSW Department of Health's Contract and Service Performance Branch has initiated a number of projects aimed at identifying and supporting better practice within the NSW health system. One of these projects was the development of Better Practice Guidelines to improve the level of identification of Aboriginal and Torres Strait or assisting organisations to adapt this training to suit local requirements;
• providing indigenous status awareness material;
• providing advice and assistance in conducting data quality assessments and assistance with analysis of results.
Islander people in the New South Wales public health system. This project was auspiced by the State Continuous Improvement Steering Committee and commenced in 1998.
The development of better practice guidelines draws on the process of 'benchmarking'. This form of quality improvement compares and contrasts the way a number of organisations perform the same function. The aim is to establish best practice, and then to introduce this practice into the other organisations.
Best practice in relation to the identification of Aboriginal and Torres Strait Islander peoples in major health data collections was established at a national meeting in November 1996. At this meeting it was agreed that the benchmark to collect information about Aboriginality would be the question and responses used by the Australian Bureau of Statistics (ABS) in the five-yearly population census (see Box above).
A survey of the current collection practices within the NSW health services identified a wide variation in the questions used to collect information describing Aboriginality or indigenous status. This finding led to the publication of a document entitled Better Practice Guidelines to improve the level of Aboriginal and Torres Strait Islander identification in the New South Wales public health system. 5 The main aim of this document is to assist health services in addressing the changes needed in their current practices to meet the above benchmark.
The publication of the Better Practice Guidelines is one strategy used to introduce change. Increasing the awareness among staff of the importance of collecting high quality data and understanding the barriers to data collection of this nature has also been targeted, as described in the second project, the development of a training program for frontline staff collecting patient registration information.
TRAINING PROGRAM FOR FRONTLINE STAFF
In 1999, the Aboriginal Health Information Strategy (AHIS) Unit developed a draft training program for frontline staff to raise the awareness about, and to improve the quality of, Aboriginal and Torres Strait Islander origin information collected in NSW hospitals. Frontline staff are clerical or clinical staff who collect patient/client registration information at the first point of contact with health services, including:
• admission or booking offices • emergency department • community health centres • ambulance services.
The draft program was piloted with over 100 frontline staff at five large public hospitals in NSW. A report of the pilot study was released in September 1999, 6 and is available from the AHIS Unit and from the AHIS intranet Web site at: internal.health.nsw.gov.au/iasd/imcs/ahisu/ publications.
The subsequent training program addresses the broader area of patient registration information, and the difficulties that can arise collecting various personal details. The program also covers issues specific to the collection of Aboriginal and Torres Strait Islander origin information. The training is being delivered statewide using two approaches:
• delivery of the program by AHIS staff to 'target' hospitals with significant numbers of Aboriginal people in their catchment area;
• training of health staff who can deliver the training program to all other public hospitals.
To supplement this work the AHIS Unit has also recently produced a pamphlet for use by all NSW Health staff to raise their awareness about the importance of accurately collecting and recording information describing the origin of Aboriginal and Torres Strait Islander people.
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CONCLUSION
It must be recognised that, despite these strategies, there are a number of factors that are likely to affect efforts to improve the quality of Aboriginal and Torres Strait Islander origin and other patient registration information. These include:
• effectively engaging people at different levels within the public health system;
• communicating with, and gaining the support of external stakeholders, in particular Aboriginal and Torres Strait Islander organisations and medical services;
• acknowledging the existence of negative attitudes towards Aboriginal and Torres Strait Islander people and how these affect their experience of the public health system, and consequently the information they provide;
• recognising the work pressures of frontline staff and providing them with better support and training;
• developing a stronger information culture that values and uses accurate health information. These issues present many challenges for the public health workforce in NSW.
The NSW Aboriginal Health Strategic Plan states that: 'In order to measure improvements and effectively target funding to programs which will improve the health of Aboriginal people, strategies are required to develop robust performance indicators, improve data collection and improve reporting processes'.
1 Aboriginality is known to be under-reported on Department of Health data collections in NSW, although it is not known to what extent. Improving the quality of information on Aboriginality in health data collections is an important part of improving the overall quality of information on Aboriginal health in NSW.
The MDC is a population-based surveillance system covering all births in NSW public and private hospitals, as well as homebirths. Births in NSW are required to be reported to the MDC under the NSW Public Health Act
QUALITY OF REPORTING OF ABORIGINALITY TO THE NSW MIDWIVES DATA COLLECTION
1991. The data are used to monitor trends and variations in mortality and morbidity of mothers and newborns, quality of care and the major risk factors for adverse outcomes for mothers and babies. The MDC encompasses all live births and stillbirths of at least 20 weeks gestation or at least 400 grams birth-weight.
METHODS
The Aboriginality of the mother, rather than the baby, is reported to the MDC, although mother's Aboriginality is frequently used as a proxy measure for the baby's Aboriginality. Consequently, maternal Aboriginality was used for this analysis.
Aboriginal or Torres Straight Islander mothers were counted as one group in the MDC up to 1997 and as two separate groups thereafter. We were therefore unable to examine trends in the quality of reporting for both these groups. For ease of reference, in this report 'Aboriginal' will be used to refer to both groups combined.
Records of births reported to the MDC were linked to birth registration records of the NSW Registry of Births, Deaths and Marriages for births occurring in the five-year period 1994-98. Records from the two files were matched using a probabilistic linkage software (Automatch). Prior to matching, residential address and mothers' name were standardised using a standardisation software (Autostan). The overall linkage rate was 96.6 per cent of MDC records (97.8 per cent of birth registration records).
Capture-recapture methods are used to adjust estimates of counts to reflect ascertainment level or undercounting. Capture-recapture was carried out using the method described by McCarty et al. 2 Analysis was carried out using SAS version 6.12. Analyses concerning geographic location were based on health area of hospital of birth as reported to the MDC. Home births were excluded from the analysis.
RESULTS
The estimated percentage of births to Aboriginal mothers in NSW, which were reported as Aboriginal in the MDC, rose from 58.7 to 64.8 per cent over the fiveyear period 1994-98 (Table 1, Figure 1 ). Reporting was better in rural hospitals than urban hospitals: in 1998 47.0 per cent of births to Aboriginal mothers in urban hospitals were reported compared to 85.6 per cent in rural hospitals, though there was a trend towards improved reporting in both urban and rural hospitals.
In 1998, the highest ascertainment rate was in hospitals in the New England Area (93.3 per cent) and the lowest in hospitals in the Northern Sydney Area (15.8 per cent) ( Table 2 ). The number of reported births to Aboriginal mothers in Northern Sydney Area hospitals was small for both the MDC and the Registry of Births, Deaths and Marriages and the estimate of total births for this Area is not very reliable, as indicated by the wide confidence intervals (8.7-23 .0 per cent).
Of the nine urban health areas, only three (Central Sydney, Wentworth, and Illawarra) had ascertainment rates of maternal Aboriginality of more than 50 per cent in 1998. All rural areas had ascertainment rates of more than 70 per cent.
DISCUSSION
In using capture-recapture methods, three conditions need to be met:
• the two systems should be independent; • all true matches and only matches should be identified; • all cases identified by the two or more surveillance systems should be true cases that occurred in the 
Leon Heron Public Health Officer South Western Sydney Public Health Unit
Sue Campbell-Lloyd Manager, Immunisation Section NSW Department of Health
This article reviews the current literature regarding HBV epidemiology, locally and internationally, and outlines current vaccination policies and immunisation procedures. The World Health Organization (WHO) estimates that about two billion people have been infected with the hepatitis B virus (HBV) worldwide, and about 350 million of them are chronic carriers. 1 About 0.5 per cent of people with acute symptomatic HBV infection will die of fulminant hepatitis, and about 20 per cent of people with chronic HBV infection will die from its long-term sequelae (chronic active hepatitis, cirrhosis and hepatocellular carcinoma). 1 The risk of becoming a chronic carrier of HBV is inversely related to the age at which infection occurs. Infected neonates have approximately 90 per cent risk of becoming chronic carriers, children aged less than seven years have about 25 per cent risk, while persons aged more than seven years have a risk of approximately five per cent. [2] [3] [4] Immunocompromised persons are more likely than persons with normal immune function to become chronic carriers. 5 Nationally, about 250 of these notifications are known to be the result of acute infection. However, there is considerable under reporting of incident cases due to inconsistent data collection. In 1996, Kaldor et al. estimated that each year in Australia approximately 100 adults and between 108 and 1,080 infants-depending on the success of the neonatal hepatitis B immunoglobulin (HBIg) and immunisation program-become chronic carriers of HBV.
HEPATITIS B: WHERE ARE WE NOW?
HEPATITIS B VACCINATION POLICY IN AUSTRALIA HB vaccines have been available in Australia since the early 1980s and were initially recommended for risk groups only. However, persons belonging to risk groups defined by risk behaviours cannot be identified as 'at risk' until after exposure to the risk behaviour. Even then, the 'at risk' individual will need to admit the risk behaviour to a vaccine provider before immunisation against HB can be offered. The proportion of each risk group vaccinated has not been sufficient to achieve control of HB. Continuing difficulties in ensuring the identification and immunisation of 'at risk' individuals lead the National Health and Medical Research Council (NHMRC) to add universal infant and pre-adolescent immunisation to its recommendations for HB prevention in 1996. 7 This recommendation followed the 1991 recommendation of WHO that HB immunisation be integrated into national immunisation programs.
8 By 1998, national or regional programs for universal infant and/or adolescent HB immunisation had been adopted in more than 100 countries.
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RESPONSE TO HEPATITIS B IMMUNISATION
HB vaccines derived from HBsAg positive plasma and from recombinant DNA technology are equally effective. 10 As age increases, the immune response (seroconversion rate and geometric mean titre) to HB vaccine decreases. • administration of the vaccine in the buttocks instead of the arm or leg. 4, [11] [12] [13] [14] [15] Freezing the vaccine is known to decrease its immunogenicity. 
NHMRC HEPATITIS B IMMUNISATION RECOMMENDATIONS AND PROGRAMS SPECIFICALLY FUNDED BY NSW HEALTH
Infants of HBsAg positive mothers.
(All pregnant women should be tested for HBsAg). Give HBIg 100 IU intramuscularly (when infant is physiologically stable-preferably <12 hours after birth-efficacy decreases markedly if HBIg is delayed >48 hours). Give the first dose of vaccine as soon as possible (and <7 days) after birth in opposite thigh to HBIg. Three further doses of hepatitis B vaccine should be given in accordance with the schedule of the universal infant immunisation program (see below).
All other infants (universal infant immunisation program)
A dose of hepatitis B vaccine at birth followed by doses given in multivalent vaccines at 2, 4, and either 6 or 12 months is now recommended for all children. If the monovalent dose at birth is missed, vaccination against hepatitis B should continue with a multivalent vaccine, following the routine schedule. Preterm babies (<32 weeks gestation) should either be vaccinated at birth and given an extra booster (using a 0, 2, 4, 6, 12 month schedule) or hepatitis B vaccine should be delayed until the baby is 2 months old and a 2, 4, 6, 12 month schedule used. Until a thimerosal-free monovalent hepatitis B vaccine is available, the latter option is preferred for preterm babies whose mothers are HBsAg negative. For preterm or term babies of carrier mothers, a birth dose of vaccine and hepatitis B immunoglobulin must be given.
All pre-adolescent children Immunisation recommended. Pre-immunisation testing for HBV markers is not recommended.
Household contacts of acute or chronic hepatitis B cases
Investigate the HBV marker status of each household member. Immunisation is recommended for those who are HBV naïve. 
Sexual contacts of acute or chronic hepatitis B cases
Injecting drug users
Immunisation recommended for those who are HBV naïve. HIV positive individuals should receive double the normal volume of vaccine at each vaccination.
Individuals with chronic liver disease and/or hepatitis C.
Immunisation recommended for hepatitis B naïve subjects.
Haemodialysis patients
Immunisation recommended. Haemodialysis patients should receive double the normal volume of vaccine at each vaccination.
Recipients of certain blood products (blood product concentrates for clotting disorders)
Immunisation recommended from the time the clotting disorder is identified.
Persons in facilities for persons with intellectual disabilities
Immunisation recommended for HBV naïve intellectually impaired persons in residential and non-residential care.
Staff of facilities for persons with intellectual disabilities
Immunisation recommended for staff involved in the care of intellectually impaired persons in residential and non-residential care.
Inmates of correctional institutions and Juvenile Justice Centres
Offer screening and immunisation.
Staff of correctional institutions and Juvenile Justice Centres
Immunisation recommended.
Health Care Workers and embalmers
Immunisation recommended for all staff directly involved in patient care, embalming or handling of human blood or tissue.
Persons adopting children from overseas
These children should be tested for hepatitis B, and if HBsAg positive members of the adoptive family should be vaccinated.
Police, armed forces, Emergency Services personnel.
Offer immunisation to those whose duties put them at increased risk.
Travellers to areas with a high prevalence of hepatitis B infection.
Offer immunisation to those who will reside in high prevalence areas for prolonged periods and those who do not wish to avoid sexual contact, injecting drug use, tattooing or body piercing while in high prevalence areas.
Contact sports
Although the risk is very low, immunisation should not be discouraged.
Accelerated schedule
In circumstances where more rapid protection is required (for example, contacts of hepatitis B carriers and vaccination of travellers), only one product, Engerix B, is registered for use in an accelerated schedule. The accelerated schedule for adults using Engerix B is 0, 7, and 21 days with a booster at 12 months. 
MANAGEMENT OF NON-RESPONDERS
In general, of those adults who make no anti-HBs response at all following the three-dose vaccination, only 10 per cent will respond to an extra dose of vaccine. While, of those who make a poor response in which anti-HBs does not rise above 10 mIU/mL, approximately 40 to 50 per cent will produce an antiHBs response of more than 100 mIU/mL in response to a fourth dose of vaccine. [17] [18] [19] [20] Administration of two or three additional doses to initial non-responder adults fails to produce an adequate anti-HBs response in up to 40 per cent. [17] [18] [19] [20] Between 68 per cent and 94 per cent of non-or poor-responder babies develop adequate anti-HBs levels in response to one or two additional doses of HB vaccine. 21, 22 
DURATION OF PROTECTION
The duration of anti-HBs following immunisation depends on the peak level of anti-HBs attained. 10, 23, 24 Approximately 90 per cent of anti-HBs is lost in the first 12 months following immunisation and thereafter antiHBs levels halve every 14 months. 24 Questions remain about the duration of protection afforded by immunisation and the need for booster doses. Based on the information available in August 1999 a committee of European HB experts concluded that, as yet, there is no need to recommend booster doses for immunocompetent individuals who have responded to the primary immunisation course. 25 The available evidence shows that immunological memory permits a protective anamnestic anti-HBs response to antigen challenge. When re-exposure to HBsAg occurs, clones of HBsAg-responsive memory B lymphocytes remaining after primary HB immunisation can expand to produce increased levels of anti-HBs as quickly as within 3-5 days, even in individuals whose anti-HBs is no longer detectable. [26] [27] [28] It is this ability to respond rapidly to HBsAg re-exposure that is thought to provide protection against clinically apparent infection. Certainly, the breakthrough infections observed to date have not produced recognised clinical hepatitis. The most common event that indicates breakthrough infection with HBV is an anamnestic rise in anti-HBs levels. 10, [29] [30] [31] This has been seen in 3.5 per cent to 20 per cent of vaccinees who belonged to populations in which HB is common and who were followed five to 12 years. 10, [29] [30] [31] Some individuals may have multiple anamnestic response episodes. 10 The frequency of these 'natural boosts' of anti-HBs did not correlate with initial post-immunisation anti-HBs levels in one study. 29 Breakthrough infections may also be shown by detection of HBsAg or by anti-HBc seroconversion. Breakthrough infection rates as determined by HBsAg detection or anti-HBc seroconversion are inversely related to initial post-immunisation anti-HBs levels. 23, 31 A study of Taiwanese children vaccinated at birth showed that lower post-immunisation anti-HBs levels were correlated with early loss of anti-HBs and increased rate of breakthrough infection. 23 Children whose anti-HBs declined to undetectable levels by age five years were more than twice as likely to become infected by age 10 years (RR 2.42, 95% CI 1.22-4.81, p=0.02) than those who retained anti-HBs. 23 In agreement with other studies, none of the breakthrough infections caused clinical manifestations. To date, this is the only study to show HBsAg carriage following breakthrough infection: three cases of HBsAg carriage occurred in children aged 1-2 years among the 113 breakthrough infections that occurred during 10 years of follow-up. 23 The authors did not report if the chronic infections were caused by vaccine escape variants of HBV. Currently, booster immunisations are not recommended for immunocompetent individuals who have lost anti-HBs. 25, 32 Immunosuppressed persons, such as those with chronic renal failure or HIV infection produce poorer anti-HBs responses than do immunocompetent individuals. 8, 15 Little data are available on the duration of immunological memory in immunocompromised persons. However, there are reports of clinically significant HBsAg positive breakthrough infections in dialysis patients who have lost anti-HBs. Booster immunisations are recommended for immunocompromised persons whose anti-HBs declines to <10mIU/mL. 34,35 However, in the early 1990s, possibly as few as 77 per cent of pregnant women may be tested for HBsAg. 36, 37 In NSW, a limited number of studies showed that poorly vaccinated risk groups include:
• men who have sex with men (28 per cent) • people working in the sex industry (28 per cent) 38 • injecting drug users (7-10 per cent) 38 • prisoners (nine per cent). 
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CURRENT IMMUNISATION RECOMMENDATIONS
Given the failure to date of the selective HB immunisation programs to control the transmission of the virus, the NHMRC has recommended the pursuit of universal infant and pre-adolescent immunisation in addition to strengthening the current selective immunisation programs that target specific at-risk groups. 7, 32 In 1999 the NSW Department of Health introduced funding for HB immunisation of all children aged 10 years and persons attending sexual health clinics and, now that suitable multi-valent vaccines that include HBsAg are available, universal immunisation of infants against HBV commenced in May 2000.
The current NHMRC recommendations for HB immunisation and the programs specifically funded by the NSW Department of Health are listed in Table 3 . Recommendations for limited follow-up of vaccinees are listed in Table 4 .
FUTURE DIRECTIONS
The poor penetration of hepatitis B vaccination into atrisk groups in which risk of exposure is determined by risk-behaviours, for example:
• injecting drug users • men who have sex with men • sex workers has resulted in the realisation that prevention of hepatitis B transmission within these at-risk groups may have to rely on the recently instituted universal childhood hepatitis B vaccination program, or await the development of more targeted vaccination programs. If pre-adolescent hepatitis B vaccination programs fail to deliver hepatitis B vaccination to a significant proportion of the population, a minimum of 15 years will pass before individuals immunised as infants begin to take up at-risk behaviours. Therefore, at-risk groups should still be targeted for hepatitis B vaccination with the development of vaccination delivery programs that are accessible and user-friendly for members of the at-risk groups. More research is needed to determine how best to overcome barriers to effective delivery of hepatitis B vaccination programs to these at-risk groups.
PROGRAM FOR ENHANCED POPULATION HEALTH INFOSTRUCTURE (PEPHI)
• How healthy are the people in my local area?
• What are the main health problems that send people to hospital in my local area?
• What are the most common preventable diseases in my local area?
The Epidemiology and Surveillance Branch of the NSW Department of Health is currently planning the Program for Enhanced Population Health Infostructure (PEPHI). The program will comprise a series of projects and initiatives designed to expand the available information on the health of the population of NSW and make that information more easily accessible. Useful and meaningful information about the health of people living in the community is central to providing health services and other public health interventions that meet community needs. The health information referred to here includes statistical data describing the health and disease status of people living in the community, the health services used by these people, and the health outcomes of those services. PEPHI is aimed at better meeting the information needs of:
• health professionals working outside the public health system, administrators, planners and policy analysts working in non-health sectors, students, and the general public;
• public health system staff at all levels;
• population health data analysts and researchers.
A discussion paper on PEPHI has been produced. Comments on the discussion paper are welcome as they will ensure that PEPHI projects and initiatives are designed to meet health information needs. Copies of the discussion paper are available from David Muscatello, and can be obtained by phoning (02) 
RESULTS
HIV Notifications
A total of 11,753 new diagnoses of HIV infection have been notified to the end of 1999 in NSW residents. Of those, between 7,200 and 9,700 were estimated to be living with HIV in 1999 ( Table 7) . HIV notifications for 1999 (389) were the lowest for any year since testing began in 1985, continuing a downward trend since the peak in 1987 ( 
DISCUSSION
These data reflect an HIV-AIDS epidemic that, in comparison with almost any country in the world, has been successfully contained in NSW to date. HIV transmission has been predominantly through male to male sexual contact in NSW. Transmission through injecting drug use is uncommon; the number of notifications that reported injecting drug use is low, and surveys of clients of needle and syringe programs report seroprevalence of less than two per cent in those that do not also report male to male sexual contact. 4 Transmission through heterosexual contact is also relatively uncommon, and the majority of cases either originated from a high prevalence country, or had sexual contact with a person from a high prevalence country. In particular, confirmed cases of heterosexual transmission, where neither partner was in a high-risk group, were rare.
The figures for AIDS cases and deaths reflect the considerable success of new combination therapies introduced in 1996. The figures for 1999 are incomplete, but after adjustment for reporting delay, a substantial decrease is still apparent. 
FACTSHEET I N F L U E N Z A WHAT IS INFLUENZA?
Influenza (known as 'the flu') is a highly contagious acute respiratory illness. It is mostly caused by two types of influenza viruses, known as A and B.
HOW IS INFLUENZA SPREAD?
The virus is spread from person to person through infectious droplets when an infected person coughs or sneezes. It is easier to catch in crowded areas and in confined spaces. Epidemics generally last several weeks and peak in NSW between June and September.
WHAT ARE THE SYMPTOMS?
• A person generally has a sudden onset of:
-fever -headache -muscle and joint pain -feeling tired -sore throat -cough -runny or stuffy nose -often extreme fatigue.
• Symptoms usually appear within 1-3 days of being infected, and a person is considered contagious for another 3-4 days after symptoms appear. Children may be infectious for seven days.
• Most people recover within 2-7 days. Compared with other viral respiratory infections like common colds, influenza causes more severe complications such as pneumonia, particularly in elderly people and other vulnerable groups.
HOW CAN INFLUENZA BE TREATED?
There are some specific drugs that can help reduce the symptoms of flu. The symptoms can also be treated with rest, good nutrition, and plenty of fluids. Medication may be required to combat fever, headache and muscle aches and pain. Antibiotics may be used if someone has a secondary bacterial infection. Your doctor can provide advice on all the appropriate medications.
HOW CAN I PREVENT INFLUENZA?
• Vaccination is the most effective protection against influenza infection. Anyone who wishes to avoid the flu should think about getting vaccinated each year well before winter begins.
• Influenza vaccination is strongly recommended for:
-all adults aged 65 years and over; -Aboriginal and Torres Strait Islander adults aged 50 years and over; -adults and children (6 months or older) with chronic diseases affecting the heart, lungs, kidneys or that require regular medical follow up and/or hospitalisation (including diabetes mellitus, asthma, and people whose immune system is suppressed); -residents of nursing homes and other long term care facilities; -children and teenagers (six months to 18 years) on long term aspirin therapy; -persons infected with HIV; -health care providers, staff of nursing homes and long-term facilities, providers of home care to persons at high risk (for example, nurses, volunteer workers), household members (including children six months or older) of persons in increased-risk groups; -travellers, especially those in large tourist groups (such as on cruise ships) or travelling to parts of the world where influenza is circulating; -women who will be pregnant during the influenza season between June and September.
• If you or a family member is diagnosed with the flu, to prevent the spread to other people, it is advisable for you or your family not to attend work, school or childcare.
WHEN SHOULD I BE VACCINATED?
The best time to be vaccinated against influenza is in autumn, prior to the winter influenza season.
WHERE CAN I RECEIVE MY VACCINATION?
Your doctor can vaccinate you with the current vaccine for the season.
WILL I HAVE TO PAY FOR THE VACCINE?
If you are 65 years or older, or are Aboriginal or Torres Strait Islander aged 50 years or older, or are 15-49 years of age, who meet the recommendations for immunisation based on the NHMRC risk factor assessment, the vaccine will be free. However, the doctor may charge a consultation fee.
IS THE VACCINE SAFE?
• Yes. The most frequent side effect of vaccination is soreness at the vaccination site, which may last up to two days.
• Mild 'flu-like' symptoms such as fever, fatigue, and muscle soreness may occur but are not common.
• Other side effects are rare; ask your doctor for further information.
IS IT POSSIBLE TO CATCH THE FLU AFTER I HAVE BEEN VACCINATED?
• It will take about two weeks for your body to develop immunity against the influenza virus after your vaccination.
• The influenza virus changes from time to time and the vaccine is designed to match the current circulating virus. The vaccine will provide about 70 per cent protection against infection for about one year. However, even if you do catch the flu, the likelihood of developing complications from the infection will be reduced.
DO I NEED TO RECEIVE A FLU VACCINE EVERY YEAR?
Yes. Annual vaccination is necessary to provide continuing protection against the most recent influenza virus.
For further information contact your doctor, community health care centre or your nearest Public Health Unit.
MEASLES RE-EMERGES
By early November, 17 cases of measles had been reported in NSW since July 2000. Of these cases, 14 resided in NSW and three were visitors, just over half were 18-30 year olds and most (70 per cent) were females. Two separate clusters of cases have been identified.
The first cluster of 10 cases, mainly young adults, has been linked to Northern Sydney. Six of the cases reside in Northern Sydney, and three others may have been infected while visiting Northern Sydney. The remaining case may have been exposed to one of these cases in an adjacent area. The cluster began with a person who returned from Malaysia with the infection in late August 2000. To date, four subsequent generations of transmission have been identified within the cluster.
The second cluster of five cases has been identified recently in children who have not been immunised in Western, South Western and Central Sydney areas. Links between four of these cases have been confirmed.
RUBELLA RE-EMERGES
By early November, 100 cases of rubella had been notified in NSW since July. Most (73 per cent) of these occurred in 18-30 year olds and in males (80 per cent). By place of residence of the patients, 40 per cent lived in the Hunter Area and 29 per cent in South Eastern Sydney.
The importance of immunisation
A single dose of MMR vaccine will provide immunity against measles, mumps and rubella to 95 per cent of those vaccinated. The NSW Department of Health is currently promoting the immunisation of young adults to reduce the ongoing transmission of these diseases including congenital rubella syndrome. In August 2000, the Federal Government announced funding over the next 12
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months to provide free MMR vaccine to persons aged between 18-30 years.
Check rubella immunity before pregnancy
Because of the potential consequences for the foetus, women should have their immunity checked prior to pregnancy, and if inadequate, be vaccinated with MMR. MMR vaccine should not be given to a woman known to be pregnant and pregnancy should be avoided for two months after vaccination.
END OF THE INFLUENZA SEASON
Reports of influenza declined sharply in October after peaking in September. Seasonal influenza surveillance (involving sentinel laboratories and general practitioners) ceased in early November.
SYPHILIS SURVEILLANCE IN CENTRAL SYDNEY Belinda O'Sullivan and Patrick Maywood
Syphilis is an acute and chronic sexually transmitted disease (STD) caused by infection with Treponema Pallidum. It is characterised by skin and mucous membrane lesions in the acute infectious phase (early syphilis) and lesions of the bone, viscera, cardiovascular and neurological systems in the chronic non-infectious phase (late syphilis). Pregnant women with syphilis who have not received adequate penicillin therapy may transmit the infection to their foetus at any clinical stage of their disease causing congenital syphilis in infants. Therefore, it is NSW Health policy to screen all mothers for syphilis.
Recent syphilis outbreaks have been reported in large cities among disadvantaged groups and men who have sex with men, and has been linked to enhanced transmission of HIV. 1, 2 While syphilis can be controlled in the community through safe sex practices and through appropriate contact tracing and treatment, the successful implementation of these strategies relies on adequate access to well-coordinated health services. 
Surveillance method
For all new syphilis notifications in the Central Sydney Area Health Service, doctors were sent a 'syphilis package' including a fact sheet, questionnaire (covering demographic details, case classification, signs and symptoms, screening and contact tracing) and criteria for accurate case classification based on serological and clinical indicators. If questionnaires were not returned within a month, they were re-mailed. Returned questionnaires were analysed using Epi Info.
Results
Of the 135 notifications for syphilis, 117 (87 per cent) questionnaires were returned (Table 8) .
Demographics
Of 117 cases, most (61 per cent) were male, the mean age was 45 years and only 31 per cent of cases were born in Australia or New Zealand. Of those born outside of Australia, country of birth was reported as Asia (18 per 
Testing
A high proportion (74 per cent) of syphilis cases were asymptomatic on presentation. Diagnosis of asymptomatic cases occurred in the context of routine sexual health screening and targeted screening of groups born in countries where syphilis is endemic. Syphilis cases were diagnosed at GP clinics (50 per cent), sexual health centres (20 per cent) and hospitals (20 per cent) . In addition, 15 (13 per cent) of cases were identified through routine antenatal screening. Of the nine 'early' or infectious cases, eight (89 per cent) were female, and three were identified through antenatal screening.
Case Classification
In the year April 1 1998 to March 31 1999, prior to upgraded surveillance, 91 per cent of syphilis notifications in Central Sydney were classified as 'unspecified'. 3 By undertaking upgraded surveillance between 1 April 1999 and 31 March 2000, 95 per cent of all notifications were classified. Only eight per cent of cases were classified as early disease and the majority of cases (84 per cent) were classified as greater than one year duration (noninfectious). Only three per cent were neurosyphilis, and no cases of congenital syphilis were recorded.
Contact tracing
One element of the upgraded surveillance system was the provision of referral support and information for doctors undertaking contact tracing. Nine cases were classified as early disease and contact tracing occurred as appropriate in all of these cases; however, it is interesting to note that doctors reported undertaking contact tracing for 50 (43 per cent) cases overall. No linked cases were identified. Sexual health centres, as a common referral source, undertook most (21 per cent) contact tracing with 17 per cent done through general practitioners and very little (three per cent) done through hospitals.
Conclusions
The upgraded surveillance system at CSPHU achieved a high questionnaire return rate which allowed the classification of 95 per cent of all syphilis compared with 53 per cent in the year prior to the upgraded surveillance.
The recent NSW Department of Health policy encouraging public health units to undertake classification of all single notifications of syphilis will be likely to improve statewide information of syphilis incidence, the detection of outbreaks, enhanced contact tracing at the local level, and will help to identify regional patterns and groups at high risk of contracting syphilis.
MANAGING DELIBERATE BIOLOGICAL INCIDENTS Louise Coole
In recent years, following well-publicised events such as the United Nations response to the Iraqi weapons programs, and the terrorist activities of the Aum Sect in Japan, international attention has increasingly focused on the identification and disarmanent of biological weapons. 
Risk management
In developing a strategy for risk management it is important to acknowledge that the likelihood of a serious biological release is low, however the consequences could be devastating. With some forward planning it may be possible to reduce the effects of such an incident.
3
The two threads of a risk-management approach are recognition and response. Since the latter depends on the former, recognition is key. The difficulty in detecting biological weapons at the point of release has been mentioned and is outside of the public health function; however, it is possible to enhance event recognition and this would most likely involve health care workers through:
• clinical case recognition • laboratory diagnostic ability • epidemiological recognition of an unusual event (that is, surveillance).
To minimise the effect of a biological event health care professionals and public health authorities must be aware of the threat, have some understanding of the classes of agents that can be involved and their effects after inhalation.
Surveillance of background disease activity in a population with follow-up of unusual events is a key component, and through close attention to patterns of disease it may be possible to recognise a situation in time to act to protect communities. An event of deliberate biological exposure could be associated with:
• a compressed epidemic curve • large epidemics • localised epidemics in multiple locations • high symptomatic rate among those exposed • an increase in respiratory infections • cases of an unusual disease • vector-borne disease in a vector free area • more than one epidemic occurring at one time • higher morbidity and mortality than expected for the disease • lower attack rates in people protected from aerosol exposure (that is, inside buildings)
• cases in animals.
There is also sometimes prior intelligence (that is, warnings from terrorist groups) and identification of a delivery vehicle. The timing of an exposure may also provide an indication of an unusual occurrence.
Incident management
Management of an incident includes:
• clinical management and therapy for cases • chemoprophylaxis of exposed persons where appropriate • vaccination of exposed persons where appropriate • dissemination of information • mechanism for mobilisation of appropriate response.
There are resource issues with respect to laboratory diagnosis, clinical management and infection-control requirements and medicines. It is necessary to determine the need for the acquisition of special stocks of pharmaceuticals-vaccines-antitoxins etc, the estimated available sources in an emergency, and to explore the mechanisms for attaining extra supplies at short notice.
Preparing for such events has cost implications. Assets invested should be appropriate to the magnitude of the threat and must be balanced against other competing health priorities. An economic analysis of preparedness measures in the United States indicates a clear costbenefit in the potential for harm minimisation in the event of an incident taking place. 4 Specific issues for forward planning include:
• defining 'exposed' populations 
Conclusion
Many countries have begun the process of planning for deliberate biological events. In NSW, public health units provide a network of public health surveillance and response teams whose job it is to identify and control infectious disease outbreaks. In addition, in recent months, NSW Health has begun a program of training for public health and emergency health workers, under the auspices of the Disaster Planning Unit. An expert advisory committee, the Risk Management Group-Biological Weapons, including experts in microbiology, infectious diseases, pharmaceuticals and public health has been established to assist in the planning process. The planning process will be ongoing.
Characteristics of biological agents suitable for weapon use.
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